Steroid phobia isn't reduced by improving patients' knowledge of topical corticosteroids
- 1 December 2020
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 83 (6) , e403-e404
Abstract
No abstract availableFunding Information
- Galderma
- GlaxoSmithKline
- Stiefel
- Almirall
- Alvotech
- LEO Pharma
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Mylan
- Celgene
- Pfizer
- Ortho Dermatology
- AbbVie
- Samsung
- Janssen
- Lilly
- Menlo
- Merck
- Novartis
- Regeneron
- Sanofi
- Novan
- Qurient
- National Biological Corporation
- Caremark
- Advance Medical
- Sun Pharma
- Suncare Research
- Informa
- Uptodate
- National Psoriasis Foundation
This publication has 5 references indexed in Scilit:
- Efficacy of targeted education in reducing topical steroid phobia: A randomized clinical trialJournal of the American Academy of Dermatology, 2020
- Assessing the Effect of Clinical Trial Evidence and Anecdote on Caregivers’ Willingness to Use Corticosteroids: A Randomized Controlled TrialJournal of Cutaneous Medicine and Surgery, 2019
- Correlations among steroid fear, acceptability, usage frequency, quality of life and disease severity in childhood eczemaJournal of Dermatological Treatment, 2015
- Maximizing patient adherence for optimal outcomes in psoriasisJournal of the European Academy of Dermatology and Venereology, 2011
- A Randomized Controlled Pilot Study of the Effects of an Extra Office Visit on Adherence and Outcomes in Atopic DermatitisArchives of Dermatology, 2010